THESSA CONFLUENCE EP DRIVER
Son Goku fought always to keep the peace and was appointed guardian of Earth and the driver Combatants Z.
This is an example of a hero that should be followed, but he was the only one who fights with good intentions reason for which drew on his side a lot of enemies. One night, Goku turns into a gorilla and kills his adoptive grandfather without accomplishing what he did. After he had returned to normal, our hero could not remember anything and with the passing years had not been able to remember how it happened. After this incident, his life has changed more and more, he was now alone in the fight with the evil. By the time he was a little child, Goku was sent on Earth from the planet Vegeta, where he was born, to destroy all the inhabitants, but along with Gohan, his grandfather, it has turned up to the defender of Earth. Reaching the age of maturity, Goku marries and makes himself a child whom they appoint as Son Gohan, in her grandfather's memory. Leukemia Research 27 Supplement Numer 1 (2003) S1–S123ħth International Symposium on Myelodysplastic Syndromes-Abstracts EPIDEMIOLOGY POLYMORPHISMS OF METABOLIZING ENZYMES (NAT2, GSTT1, GSTM1 AND GSTP1) IN DE NOVO AND THERAPY-INDUCED MDS AND AML D. Trümper Department of Hematologgy/Oncology, University of Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany ∗ E-mail: Glutathione S-transferases (GST) and N-acetyltransferases metabolise exogenous and endogenous compounds. Recent studies examined the role of these enzymes in carcino- and leukemogenesis. Thus, further efforts are needed to clarify the relevance of polymorphisms of metabolising enzymes for the pathogenesis of de novo and secondary malignancies. Recently, our group could demonstrate a significantly increased risk for t-AML/MDS after breast cancer-therapy in individuals with a double deletion of GSTT1 and GSTM1. To extend our database by a higher number of individuals examined and by determining the occurrence of NAT2and two GSTP1-polymorphisms (Exon 5: Ile105Val and Exon 6: Ala114Val). GSTP1-poymorphisms were analysed in blood samples or bone marrow of 326 patients (180 AML, 146 MDS) of whom 65 had therapy-related malignancies (t-AML/t-MDS) by PCR/RFLP analysis. Data were compared with the results of 266 healthy controls. The polymorphisms of GSTT1 and GSTM1 were examined in 439 patients (265 AML, 174 MDS, 65 t-AML/MDS) and compared with 248 healthy controls. NAT2-polymorphisms (fast metabolisers, heterozygotes and slow metabolisers) were analysed in 352 patients (196 AML, 156 MDS, 28 t-AML/MDS) and compared with 240 controls. Patients were sub-grouped according to cytogenetics (normal, non-complex, complex) and in t-AML/MDS according to primary malignancy (Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL) and breast cancer). The analysis of NAT2 revealed no significant differences between controls and any patient subgroup. P = 0.0353 (according to two-sided Fisher’s exact test).
0 kommentar(er)
